CHIMAGEN-CMG1A46-US01
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager CMG1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-cell Hematologic
Malignancies
IIT-ATALLAH-MCW-XEN21
Phase I
OPEN TO ACCRUAL
A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma